The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
bio-rad price target lowered by ubs amid economic concerns
UBS has cut Bio-Rad's price target to $310 from $355 while maintaining a Buy rating, citing macroeconomic concerns despite the company's quarterly performance meeting expectations. Analysts forecast an average target of $349.83, indicating a potential upside of 44.92% from the current price of $241.39. Positive developments include exceeding revenue estimates and growth in the bioproduction sector, while challenges persist in sales and margins.
lateral flow assay market analysis trends and growth opportunities 2024 to 2031
Priya Pandey, a biotechnology graduate, excels in creating engaging content across various industries, including healthcare and technology. Coherent Market Insights offers comprehensive market intelligence and consulting services, providing detailed reports on sectors like food and beverages and pharmaceuticals, with insights into market dynamics and competitive strategies. The latest report on the Lateral Flow Assay Market forecasts trends and growth from 2024 to 2031, analyzing consumer behavior and regulatory factors while highlighting key players and emerging opportunities.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.